OncoSec is a biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Through its proprietary DNA gene transfer technology, OncoSec seeks to deliver safer and more effective cancer treatments that can provide long-term benefits for patients who have limited or no available treatment options. OncoSec’s technology combines TAVO™ (tavokinogene telseplasmid), an intratumoral (IT) DNA plasmid-based interleukin-12 (IL-12) designed to achieve targeted and sustained delivery of IT IL-12. TAVO has demonstrated a local and systemic anti-tumor response in several clinical trials, including preliminary data in a registration directed Phase 2b trial KEYNOTE-695 for anti-PD-1 checkpoint refractory metastatic melanoma and the KEYNOTE-890 Phase 2 trial in metastatic triple-negative breast cancer (mTNBC). To date, preliminary study results have laid the groundwork for the expansion into new DNA-encoded therapeutic candidates and tumor indications. OncoSec plans to develop TAVO, along with other immunologic genes to treat other cancer indications. OncoSec has received both Orphan Drug and Fast-Track Designation by the U.S. Food & Drug Administration for TAVO in metastatic melanoma. NASDAQ: $ONCS
View Top Employees from OncoSecWebsite | http://www.oncosec.com |
Ticker | ONCS |
Revenue | $440000 |
Funding | $33.9 million |
Employees | 37 (37 on RocketReach) |
Founded | 2011 |
Address | 3536 General Atomics Ct, San Diego, California 92121, US |
Phone | (858) 210-7333 |
Technologies |
JavaScript,
HTML,
Twitter
+25 more
(view full list)
|
Industry | Biotechnology Research, Medical Testing & Clinical Laboratories, Biotechnology, Oncology, Healthcare, Science and Engineering, Cancer Treatment, Health Care, Drug Development, Life Science, Immunotherapy, Life Sciences, Clinical Development |
Web Rank | 2 Million |
Keywords | Sunscreen Vs Sunblock, Does Chemotherapy Use Gamma Rays, Oncosec Board Of Directors, The Sun And Autoimmune Disease, Life Expectancy With Untreated Melanoma |
Competitors | Altor Bioscience Corporation, Eureka Therapeutics, Inc, Jounce Therapeutics, Inc., Morphogenesis, Inc., iTeos Therapeutics |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 541 Companies, NAICS Code 54138 Companies, NAICS Code 5413 Companies, NAICS Code 54 Companies |
Looking for a particular OncoSec employee's phone or email?
The OncoSec annual revenue was $440000 in 2024.
37 people are employed at OncoSec.
OncoSec is based in San Diego, California.
The NAICS codes for OncoSec are [541, 54138, 5413, 54].
The SIC codes for OncoSec are [87, 873].